Literature DB >> 6850537

Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes.

G M Mavligit, S Stuckey.   

Abstract

Significant increments in measurable plasma CEA were effected by 2.5 M MgCl2 elution from putative circulating CEA-anti-CEA complexes in 11 of 15 patients with disseminated colorectal cancer and in five of ten patients with a high probability of having subclinical disease (Dukes'C category). Following 2.5 M MgCl2 elution, IgG from a patient with a high CEA increment effected a higher specific binding to 125I-CEA than a similar IgG eluate from a patient with a negligible increment in measurable CEA. These data suggest that CEA is autoimmunogenic and may result in circulating CEA-anti-CEA complex formation. The clinical implications of such complexes in the diagnosis and monitoring of patients with colorectal cancer remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850537     DOI: 10.1002/1097-0142(19830701)52:1<146::aid-cncr2820520126>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Circulating immune complexes in HIV-infected persons.

Authors:  F E Krapf; M Herrmann; W Leitmann; B Schwartländer; J R Kalden
Journal:  Klin Wochenschr       Date:  1990-03-16

2.  Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer.

Authors:  K A Chester; R H Begent
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

3.  CEA-containing immune complexes in sera of patients with colorectal and breast cancer--analysis of complexed immunoglobulin classes.

Authors:  C Fuchs; F Krapf; P Kern; S Hoferichter; W Jäger; J R Kalden
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 4.  Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.

Authors:  A P Zbar; N R Lemoine; M Wadhwa; H Thomas; D Snary; W A Kmiot
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.